NSE ScannerPharmaceuticals · Biotechnology · NSE: FERMENTA · data 2026-11-01
Fermenta Biotech Ltd
In plain words
Price: 28.3% below its 52-week high of ₹582.65.
Delivery: 43.5% of traded shares were kept for delivery over the last 10 sessions, against 46.2% over the last 60.
Latest results: a net profit of ₹10 cr for the quarter ended Jun 2026.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹511 cr |
| Net profit (last 12 months) | ₹60 cr |
| Sales growth, 3 years (yearly) | 14.5% |
| Profit growth, 3 years (yearly) | — |
At a glance
Promoters 60.1%, pledged 0.0%, institutions 1.1%.
P/E 20.1, dividend yield 0.9%. Price relative to earnings and book value (low is cheaper, not better).
ROE 18.7%, ROCE 20.8%, operating margin 13.4%: how much profit it earns on the money it uses.
Debt/equity 0.28, Profit growth — and sales growth 14.5% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- High return on equity (18.7%).
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q1 FY27)
FERMENTA Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹121.82 crore.
Net profit was ₹9.74 crore.
Operating margin was 14.8%.
EPS was ₹3.4.
FERMENTA के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹121.82 करोड़।
शुद्ध मुनाफ़ा: ₹9.74 करोड़।
ऑपरेटिंग मार्जिन: 14.8%।
EPS: ₹3.4।
FERMENTAના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹121.82 કરોડ.
ચોખ્ખો નફો: ₹9.74 કરોડ.
ઓપરેટિંગ માર્જિન: 14.8%.
EPS: ₹3.4.
Written from the filed numbers. Not a recommendation.
Smart-money activity
5/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Delivery 34.7% over the last 20 sessions vs 36.0% in the 40 before (0.96x); shares delivered per day 0.5x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: Net −₹32.15 cr in bulk/block deals over 90 days (0 net buying days, 1 net selling day): more sold than bought.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Deal ● Results ● Dividend
- 28 Sept 26Deal Bulk deal: THAKKAR PREETI sold ₹55.34 cr (net −₹32.15 cr) +17.7% next session
- 11 Aug 26Results Q1 FY27 results: net profit ₹9.7 cr -13.6% next session
- 5 Aug 26Dividend Dividend ₹3.75 (ex-date) +1.0% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹122 cr | ₹10 cr | — | 14.8% | 3.4 |
Shareholding trend
| Holder | Sept 2026 |
|---|---|
| Promoters | 60.12% |
| Foreign institutions (FII) | 1.05% |
| Domestic institutions (DII) | 0.00% |
| Mutual funds | 0.00% |
| Retail investors | 20.64% |
| Number of shareholders | 16,084 |
Common questions
What was Fermenta Biotech Ltd's latest quarterly profit?
Fermenta Biotech Ltd reported a net profit of ₹10 cr for the quarter ended Jun 2026, on revenue of ₹122 cr.
How much do promoters hold in Fermenta Biotech Ltd?
Promoters held 60.12% of Fermenta Biotech Ltd at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Fermenta Biotech Ltd debt-free?
Its latest reported debt-to-equity ratio is 0.28.
What is Fermenta Biotech Ltd's P/E ratio?
About 20.2, based on the last 12 months' earnings and a price of ₹417.55 (data 2026-11-01).
What is the 52-week high and low of Fermenta Biotech Ltd?
The 52-week high is ₹582.65 and the 52-week low is ₹248.85.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Fermenta Biotech Ltd | ₹417.55 | ₹1,229 cr | 20.2 | — | 18.7% | 20.8% | 0.28 | +34.7% |
| Anthem Biosciences Limited | ₹828.8 | ₹46,685 cr | 81.7 | — | 21.7% | 26% | 0.02 | +13.6% |
| Rubicon Research Limited | ₹1,610.5 | ₹26,650 cr | 92.7 | — | 27% | 32.4% | 0.24 | +168.0% |
| Akums Drugs and Pharmaceuticals Limited | ₹731.7 | ₹11,520 cr | 38.4 | — | 8% | 9.8% | 0.05 | +55.4% |
| Fabtech Technologies Limited | ₹123.9 | ₹547 cr | 14.1 | 1.3 | 12.9% | 9.1% | 0.17 | -48.7% |
| Haleos Labs Ltd. | ₹1,394.4 | ₹411 cr | 26.7 | — | 8.4% | 10.4% | 0.52 | +22.2% |
Compare FERMENTA with ANTHEM in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open FERMENTA in NSE Scanner →